Back to Search
Start Over
Serum levels of hsa‐miR‐16‐5p , hsa‐miR‐29a‐3p , hsa‐miR‐150‐5p , hsa‐miR‐155‐5p and hsa‐miR ‐ 223‐3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study
- Source :
- International Journal of Cancer, International Journal of Cancer, Wiley, 2020, ⟨10.1002/ijc.32894⟩, Casabonne, D, Benavente, Y, Seifert, J, Costas, L, Armesto, M, Arestin, M, Besson, C, Hosnijeh, F S, Duell, E J, Weiderpass, E, Masala, G, Kaaks, R, Canzian, F, Chirlaque, M-D, Perduca, V, Mancini, F R, Pala, V, Trichopoulou, A, Karakatsani, A, La Vecchia, C, Sanchez, M-J, Tumino, R, Gunter, M J, Amiano, P, Panico, S, Sacerdote, C, Schmidt, J A, Boeing, H, Schulze, M B, Barricarte, A, Riboli, E, Olsen, A, Tjønneland, A, Vermeulen, R, Nieters, A, Lawrie, C H & de Sanjose, S 2020, ' Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study ', International Journal of Cancer, vol. 147, no. 5, pp. 1315-1324 . https://doi.org/10.1002/ijc.32894, International Journal of Cancer, 147(5), 1315-1324. Wiley-Liss Inc., International Journal of Cancer, 147(5), 1315. Wiley-Liss Inc.
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- Chronic lymphocytic leukemia (CLL) is an incurable disease accounting for almost one-third of leukemias in the Western world. Aberrant expression of microRNAs (miRNAs) is a well-established characteristic of CLL, and the robust nature of miRNAs makes them eminently suitable liquid biopsy biomarkers. Using a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), the predictive values of five promising human miRNAs (hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p), identified in a pilot study, were examined in serum of 224 CLL cases (diagnosed 3 months to 18 years after enrollment) and 224 matched controls using Taqman based assays. Conditional logistic regressions were applied to adjust for potential confounders. The median time from blood collection to CLL diagnosis was 10 years (p25–p75: 7–13 years). Overall, the upregulation of hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p was associated with subsequent risk of CLL [OR1∆Ct-unit increase (95%CI) = 1.42 (1.18–1.72), 1.64 (1.31–2.04) and 1.75 (1.31–2.34) for hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p, respectively] and the strongest associations were observed within 10 years of diagnosis. However, the predictive performance of these miRNAs was modest (area under the curve
- Subjects :
- Oncology
Male
DOWN-REGULATION
Cancer Research
PROGNOSIS
Chronic lymphocytic leukemia
ACTIVATION
0302 clinical medicine
mir-223
Odds Ratio
Prospective Studies
Prospective cohort study
ComputingMilieux_MISCELLANEOUS
Area under the curve
Middle Aged
MIR-155
3. Good health
European Prospective Investigation into Cancer and Nutrition
Up-Regulation
Europe
DIFFERENTIATION
INFECTIONS
030220 oncology & carcinogenesis
embryonic structures
Monoclonal B-cell lymphocytosis
Female
B-CELL LYMPHOCYTOSIS
Life Sciences & Biomedicine
prospective study
EXPRESSION
medicine.medical_specialty
MICRORNA SIGNATURE
miR-155
03 medical and health sciences
Predictive Value of Tests
Internal medicine
medicine
Biomarkers, Tumor
Humans
1112 Oncology and Carcinogenesis
Oncology & Carcinogenesis
Liquid biopsy
Science & Technology
business.industry
medicine.disease
Leukemia, Lymphocytic, Chronic, B-Cell
body regions
circulating miRNA
MicroRNAs
Case-Control Studies
chronic lymphocytic leukemia
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
business
serum
CLL
Subjects
Details
- Language :
- English
- ISSN :
- 00207136 and 10970215
- Database :
- OpenAIRE
- Journal :
- International Journal of Cancer, International Journal of Cancer, Wiley, 2020, ⟨10.1002/ijc.32894⟩, Casabonne, D, Benavente, Y, Seifert, J, Costas, L, Armesto, M, Arestin, M, Besson, C, Hosnijeh, F S, Duell, E J, Weiderpass, E, Masala, G, Kaaks, R, Canzian, F, Chirlaque, M-D, Perduca, V, Mancini, F R, Pala, V, Trichopoulou, A, Karakatsani, A, La Vecchia, C, Sanchez, M-J, Tumino, R, Gunter, M J, Amiano, P, Panico, S, Sacerdote, C, Schmidt, J A, Boeing, H, Schulze, M B, Barricarte, A, Riboli, E, Olsen, A, Tjønneland, A, Vermeulen, R, Nieters, A, Lawrie, C H & de Sanjose, S 2020, ' Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study ', International Journal of Cancer, vol. 147, no. 5, pp. 1315-1324 . https://doi.org/10.1002/ijc.32894, International Journal of Cancer, 147(5), 1315-1324. Wiley-Liss Inc., International Journal of Cancer, 147(5), 1315. Wiley-Liss Inc.
- Accession number :
- edsair.doi.dedup.....b49a908d89bde8e28e33e14a09b4f5c8